UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

_______________________________

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

 

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): December 15, 2014

 

Sevion Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware 001-31326 84-1368850
(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

 

4045 Sorrento Valley Boulevard., San Diego, CA 92121
(Address of Principal Executive Offices) (Zip Code)

 

858-909-0749

(Registrant's telephone number,

including area code)

 

 

___________________Not applicable_____________________

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
  
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
  
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
  
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

 
 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On December 15, 2014, Sevion Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Meeting”). The matters voted on by stockholders at the Meeting included (1) a proposal to elect eight (8) directors to serve until the next Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified, (2) a proposal to approve the amendment and restatement of the Company’s 2008 Incentive Compensation Plan, and (3) a proposal to ratify the appointment of McGladrey LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2015. There were represented at the Meeting, either in person or by proxy, 8,330,155 shares of the Company’s common stock out of a total number of 13,866,627 shares of the Company’s common stock outstanding as of the record date, October 22, 2014, and entitled to vote at the Meeting. The results of the stockholders’ votes are as follows:

 

Proposal For Withheld

Broker Non-Votes

 

Election of the nominees to the Board of
Directors of the Company:		      
Harlan W. Waksal, M.D. 5,251,110 26,732 3,052,313
Phillip Frost, M.D. 5,192,866 84,976 3,052,313
Ronald A. Martell 5,251,606 26,236 3,052,313
John N. Braca 5,251,708 26,134 3,052,313
Christopher Forbes 5,253,486 24,356 3,052,313
David Rector 5,240,722 37,120 3,052,313
Vaughn Smider, M.D., Ph.D. 5,252,193 25,649 3,052,313
Steven Rubin 5,192,068 85,774 3,052,313

 

To approve the amendment and
restatement of the Company’s 2008
Incentive Compensation Plan.

 

For

 

5,046,582

 

 

Against

 

110,132

 

 

Abstain

 

121,128

 

 

Broker Non-Votes

 

3,052,313

         
To ratify the appointment of
McGladrey LLP as the Company’s
independent registered public
accounting firm for the fiscal year
ending June 30, 2015.

 

For

 

8,205,893

 

 

Against

 

97,886

 

 

Abstain

 

26,376

 

  

 

The foregoing votes reflect that (i) the nominees of the Board of Directors, (ii) the approval of the amendment and restatement of the Company’s 2008 Incentive Compensation Plan, and (iii) the ratification of the appointment of the Company’s independent public accounting firm for the fiscal year ending June 30, 2015, having received the votes listed above, being a plurality, majority or requisite majority of the votes cast, as applicable, were duly passed by the stockholders of the Company.

 

Item 8.01 Other Information.

 

A copy of the presentation delivered at the Meeting will be posted on our website at www.seviontherapeutics.com.

 

 

 
 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

  SEVION THERAPEUTICS, INC.
   
   
Dated: December 17, 2014 By: /s/ Ronald A. Martell  
    Name: Ronald A. Martell
    Title: Chief Executive Officer